Form 4: Neumora Therapeutics Director Matthew K. Fust Reports Stock Transactions

Director Matthew K. Fust of Neumora Therapeutics, Inc. reports multiple transactions involving common stock, including acquisitions through option exercises and sales under a 10b5-1 trading plan.

Summary

• Matthew K. Fust, a director at Neumora Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On October 17 and 18, 2024, Fust exercised stock options to acquire shares of common stock at prices of $8.32, $8.79, and $2.52.
• Concurrently, Fust sold shares of common stock on the same dates at weighted average prices of $17.0103 and $17.0346, respectively, under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Fust's directly held common stock amounts to 20,100 shares.
• Fust also holds options to purchase a significant number of Neumora Therapeutics' common stock at various exercise prices.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing reflects routine transactions under a pre-arranged trading plan. The exercise of options is a positive sign, but the sales are a neutral factor.

Positives

• The exercise of stock options demonstrates Fust's belief in the long-term potential of Neumora Therapeutics.
• The existence of a pre-arranged 10b5-1 trading plan suggests that the sales were planned and not based on recent inside information.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be interpreted negatively by some investors.

Risks

• Market reaction to the reported transactions could impact the stock price of Neumora Therapeutics.
• Continued sales under the 10b5-1 trading plan could exert downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing sales under the 10b5-1 trading plan suggest continued transactions.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in the pharmaceutical industry, with companies like Eli Lilly and Company and Pfizer also seeing regular Form 4 filings from their executives and directors.
• The use of 10b5-1 trading plans is common among corporate insiders to avoid accusations of insider trading, aligning with practices seen at companies like Amgen and Biogen.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• Monitor future Form 4 filings by Matthew K. Fust and other Neumora Therapeutics insiders.
• Assess the impact of continued sales under the 10b5-1 trading plan on the stock price.

Key Dates